Pradžia › Krono liga › Washington
Krono liga klinikiniai tyrimai Washington
22 tyrimai dėl Krono liga ieško dalyvių vietose Washington.
Miestai Washington
Oficialus tyrimo tekstas (anglų kalba)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
Renkami dalyviai3 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-10-02 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Washington ( Site 5115), Seattle
- Washington Gastroenterology - Tacoma ( Site 5004), Tacoma
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-10-02 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
- Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
- The Vancouver Clinic /ID# 280497, Vancouver
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- GI Alliance, Bellevue
Renkami dalyviai4 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-30 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Virginia Mason Hospital and Medical Center /ID# 265574, Seattle
- Washington Gastroenterology - Tacoma /ID# 267302, Tacoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University of Washington Medical Center, Seattle
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington Gastroenterology - Tacoma, Tacoma
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Bellevue-Site Number: 8400143, Bellevue
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Washington Gastroenterology- GIA, Tacoma
Renkami dalyviai4 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-09 · NCT06045754Familial Inflammatory Bowel Disease Early Risk
- Seattle Children's Hospital, Seattle
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 0 iki 55 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07791862A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Seattle Children's Hospital, Seattle
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-08-24 · NCT05509777A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- MultiCare Institute for Research & Innovation, Tacoma
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Multicare Health System Institute for Research and Innovation, Tacoma
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-06-22 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Seattle Children's Hospital, Seattle
Renkami dalyviai4 fazė
Amžius nuo 6 iki 17 · Visoms lytims · Atnaujinta 2026-05-27 · NCT05781152A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Swedish Cancer Institute, Seattle
- University of Washington Medical Center - Montlake, Seattle
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-05-27 · NCT06227910Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- University of Washington, Seattle
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-04-27 · NCT06456593Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
- Seattle Children's Hospital, Seattle
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 6 iki 21 · Visoms lytims · Atnaujinta 2026-04-24 · NCT06315179A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bellevue
- Mirador Therapeutics Selected Site, Silverdale
- Mirador Therapeutics Selected Site, Tacoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-03-12 · NCT07113522Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
- Seattle Children's Hospital, Seattle
Renkami dalyviai
Amžius nuo 8 iki 21 · Visoms lytims · Atnaujinta 2025-06-12 · NCT06216899Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.